Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2008 Jul;8(7):865-74. doi: 10.1517/14712598.8.7.865 .

Maximizing dendritic cell migration in cancer immunotherapy.

Author information

1
Radboud University Nijmegen Medical Centre, Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Geert Grooteplein 28, Nijmegen, The Netherlands.

Abstract

BACKGROUND:

The success of dendritic cell (DC)-based immunotherapy in inducing cellular immunity against tumors is highly dependent on accurate delivery and trafficking of the DC to T-cell-rich areas of secondary lymphoid tissues.

OBJECTIVE:

To provide an overview of DC migration in vivo and how migration to peripheral lymph nodes might be improved to optimize DC therapy.

METHODS:

We focused on DC migration in preclinical models and human skin explants and on clinical vaccination trials studying migration of in vitro-generated DC.

RESULTS/CONCLUSIONS:

DC migration requires an intricate interplay between the cell and its environment. To maximize migration for cellular therapy, it is important to optimize the generation of migratory DC as well as treatment strategies.

PMID:
18549318
DOI:
10.1517/14712598.8.7.865
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center